A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Latest Information Update: 22 May 2024
At a glance
- Drugs Canakinumab (Primary) ; Nisevokitug (Primary) ; Sabatolimab (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 15 May 2024 Status changed from active, no longer recruiting to discontinued.
- 05 Mar 2024 Planned End Date changed from 2 Apr 2024 to 16 May 2024.
- 05 Mar 2024 Planned primary completion date changed from 2 Apr 2024 to 16 May 2024.